Oric Pharmaceuticals Inc. (ORIC) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

ORIC scores 29 out of 100, graded E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

• Fundamental Cash Engine: 7 / 20. this reflects ROIC of -33.4% and FCF yield of -11.99%. For a prospective investor, negative returns on invested capital and negative free cash flow indicate that the business is currently consuming capital rather than generating it.
• Whale 13F Flow: 3 / 20. this pillar covers institutional accumulation and options positioning. The low score suggests limited institutional support in the rating's framework.
• Insider Conviction: 3 / 20. this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The low score is consistent with the CFO Form 4 sale reported in the news wire (see Recent Catalysts). Insider selling is one input among many and does not by itself establish a directional outcome.
• Macro Regime Fit: 6 / 20. beta of 1.0 and sector sensitivity drive this score. A beta of 1.0 implies market-like volatility relative to the broader market; the score indicates limited regime-based support.
• Forensic Balance Sheet: 10 / 20. Altman Z of 2.5, Piotroski F of 2/9, and Debt/Equity of 0.5 drive this score. The Piotroski reading is weak, and the Altman figure sits in the range the rating treats as a moderate-risk area; the Debt/Equity figure is comparatively contained.

Taken together, the rating frames ORIC as carrying elevated forensic and fundamental risk with weak institutional and insider signals. A prospective investor should weigh the cash-burn profile heavily against any upside thesis that depends on future clinical or commercial milestones, none of which are quantified in the source data.

Oric Pharmaceuticals Inc. Is a NASDAQ-listed company in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry,. Reported revenue is — across the FY 2023–FY 2025 periods shown in the SEC financials. Market capitalization is $0.9B.

Reported revenue is — in each period and operating income and net income are negative throughout. Gross, operating, and net margins are each recorded as 0% in the market data. ROIC is -33.4% and the Altman Z-Score is 2.5, while the Piotroski F-Score is 2/9. Reported cash declined from $59.4M in FY 2024 to $45.

• 🐂 Primary Bull Case: Analysts at Wedbush and Stifel maintain Outperform and Buy ratings with $14 and $18 price targets, and the news wire reports shares climbing 8.5% on an analyst upgrade. With Fundamental Cash Engine at 7/20 (ROIC -33.4%, FCF yield -11.99%) and Institutional Whale Flow at 4/20, sustained execution supports upside toward the top of the $7.23 – $14.68 52-week range.
• 🐻 Primary Bear Case: Negative ROIC of -33.4%, negative FCF of -$111.7M in FY 2025, and a Piotroski F-Score of 2/9 indicate a business consuming capital with weak forensic health. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

The source data therefore does not identify upstream suppliers, downstream customers, or sector correlations for ORIC.

• Key Question #1: What are ORIC's products, clinical programs, or commercial partnerships, and what are their timelines?
• Key Question #2: What is the company's current debt balance, given Debt is recorded as N/A across all periods?
• Key Question #3: What drives the reported cash decline and what is the runway at the FY 2025 burn rate?